Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR OTCMKTS:CXRXF NASDAQ:SRRK NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.06+1.2%$19.24$9.57▼$29.34$3.88B12.02 million shs222,880 shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsSRRKScholar Rock$31.01-1.8%$35.34$6.76▼$46.98$2.99B0.361.29 million shs75,063 shsTLXTelix Pharmaceuticals$9.63+3.6%$12.95$8.93▼$30.36$3.26BN/A62,345 shs93,510 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+2.06%+7.98%+68.88%+65.65%+27.44%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%SRRKScholar Rock0.00%-4.65%-1.16%-4.33%+271.97%TLXTelix Pharmaceuticals+2.65%-1.48%-18.08%-45.48%+928,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.06+1.2%$19.24$9.57▼$29.34$3.88B12.02 million shs222,880 shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsSRRKScholar Rock$31.01-1.8%$35.34$6.76▼$46.98$2.99B0.361.29 million shs75,063 shsTLXTelix Pharmaceuticals$9.63+3.6%$12.95$8.93▼$30.36$3.26BN/A62,345 shs93,510 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+2.06%+7.98%+68.88%+65.65%+27.44%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%SRRKScholar Rock0.00%-4.65%-1.16%-4.33%+271.97%TLXTelix Pharmaceuticals+2.65%-1.48%-18.08%-45.48%+928,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1453.75% UpsideCXRXFADVANZ PHARMA 0.00N/AN/AN/ASRRKScholar Rock 3.20Buy$45.7547.51% UpsideTLXTelix Pharmaceuticals 2.80Moderate Buy$22.33132.03% UpsideCurrent Analyst Ratings BreakdownLatest CXRXF, TLX, SRRK, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $45.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$53.007/28/2025ARWRArrowhead PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025SRRKScholar RockCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,092.84N/AN/A$1.54 per share18.22CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63SRRKScholar RockN/AN/AN/AN/A$3.94 per shareN/ATLXTelix Pharmaceuticals$516.72M6.30$0.12 per share79.25$1.12 per share8.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)CXRXFADVANZ PHARMA-$74.86MN/AN/A∞N/A-15.31%N/A-4.38%N/ASRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0020.05N/AN/AN/AN/AN/ALatest CXRXF, TLX, SRRK, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87CXRXFADVANZ PHARMA257.042.391.61SRRKScholar Rock0.216.336.33TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%CXRXFADVANZ PHARMAN/ASRRKScholar Rock91.08%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%CXRXFADVANZ PHARMAN/ASRRKScholar Rock13.30%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableSRRKScholar Rock14096.13 million83.34 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/ACXRXF, TLX, SRRK, and ARWR HeadlinesRecent News About These CompaniesTelix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer DiagnosisSeptember 9 at 7:00 PM | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 7 at 8:22 PM | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 5, 2025 | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low - What's Next?September 5, 2025 | marketbeat.comTelix Pharmaceuticals (ASX:TLX) Hits New Low Amid FDA ScrutinySeptember 5, 2025 | thebull.com.auTTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - What's Next?September 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXSeptember 3, 2025 | prnewswire.comTelix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response LetterSeptember 2, 2025 | finance.yahoo.comFY2026 Earnings Forecast for TLX Issued By William BlairSeptember 2, 2025 | marketbeat.comResearch Analysts Set Expectations for TLX FY2026 EarningsSeptember 2, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 31, 2025 | marketbeat.comWilliam Blair Has Bearish Estimate for TLX FY2027 EarningsAugust 31, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for TLXAugust 31, 2025 | marketbeat.comWilliam Blair Has Pessimistic View of TLX FY2027 EarningsAugust 31, 2025 | americanbankingnews.comFY2025 EPS Estimate for Telix Pharmaceuticals Cut by AnalystAugust 31, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low - Here's What HappenedAugust 30, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from WedbushAugust 30, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)August 30, 2025 | americanbankingnews.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens BermanAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 29, 2025 | globenewswire.comHealth Check: Angry investors birch Telix shares after third US regulatory setbackAugust 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCXRXF, TLX, SRRK, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$28.06 +0.33 (+1.19%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Scholar Rock NASDAQ:SRRK$31.01 -0.57 (-1.79%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Telix Pharmaceuticals NASDAQ:TLX$9.62 +0.34 (+3.61%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
